Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc., trading under the ticker symbol VOR, is at the forefront of cell and genome engineering, specifically focusing on hematopoietic stem cells (HSCs). Headquartered in Cambridge, Massachusetts, Vor Bio aims to revolutionize the treatment of hematological cancers, particularly acute myeloid leukemia (AML). The company’s pioneering platform involves engineering hematopoietic stem cells (eHSCs) to generate healthy and functional cells with beneficial modifications. These modifications protect the blood and bone marrow from the adverse effects of antigen-targeted therapies while leaving cancer cells vulnerable.
Key Products and Innovations:
- VOR33 (Trem-cel) - Vor Bio’s lead program, a CRISPR/Cas9 genome-edited allogeneic HSC transplant that lacks the CD33 protein. This product is designed to replace standard transplants for AML patients and potentially other blood cancers.
- VCAR33ALLO - A CD33-directed CAR-T cell therapy derived from healthy transplant donor cells. This approach aims to provide more potent and durable responses in the post-transplant setting without on-target toxicity.
Recent Achievements and Collaborations:
- Secured a non-exclusive worldwide license from Editas Medicine for ex-vivo Cas9 gene-edited HSC therapies.
- Partnership with Janssen for the preclinical development of CD33-deleted allografts and their synergistic effects with Janssen's CD33-targeted immunotherapy candidate.
Clinical Trials and Research:
- VBP101 Clinical Trial - Ongoing Phase 1/2a study of trem-cel in AML patients, showing promising engraftment results and hematologic protection.
- VCAR33ALLO Clinical Trial (VBP301) - A Phase 1/2 study involving CAR-T cell therapy derived from healthy transplant donors, showing initial successful dosing and manufacturing capabilities.
Financial Updates: In its latest quarterly report, Vor Bio announced positive financial outcomes, including an extended cash runway into the second half of 2025. The company is focused on executing its clinical trials and expanding its platform to include additional innovative therapies.
Future Outlook: Vor Bio is set to present at major scientific conferences, including the American Society of Hematology (ASH) Annual Meeting, where it will share significant preclinical and clinical data. The company is also looking forward to additional data releases from its clinical trials by year-end, which could further validate their treatment system for AML.
For more updates, visit www.vorbio.com.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The company will engage in a fireside chat scheduled for Wednesday, February 12th at 12:00pm ET and conduct virtual one-on-one meetings with investors.
The event will be held virtually, and interested parties can access both the live webcast and archived replay of the fireside chat through the investors section of www.vorbio.com.
Vor Bio (Nasdaq: VOR) has appointed Mr. Erez Kalir to its Board of Directors, creating a new board seat following a recent private investment in public equity (PIPE) financing led by Reid Hoffman. Kalir will serve as director designee of Hoffman's investment fund, Reprogrammed Interchange,
Currently Managing Member of Martial Eagle Fund and Venture Partner at FJ Labs, Kalir brings extensive experience in biotech investments and entrepreneurship. He authors the Biotech Frontiers newsletter for Porter & Co. and previously worked at Tiger Management with Julian H. Robertson, advising on biotech and healthcare investments.
Kalir's appointment strengthens Vor Bio's leadership as the company advances its trem-cel platform and VCAR33 through regulatory approval. His background includes an MSc in cell biology from Oxford as a Rhodes Scholar, a JD from Yale Law School, and an A.B. from Stanford University.
Vor Bio (Nasdaq: VOR) has secured a $55.6 million private placement investment (PIPE), led by new investor Reid Hoffman with participation from existing stockholder RA Capital Management. The company will issue approximately 55.9 million shares of common stock and warrants to purchase about 69.8 million shares at $0.99425 per share and accompanying warrants. The warrants, exercisable through 2031 at $0.838 per share, could generate additional proceeds of up to $58.5 million.
The company plans to announce updated clinical data from two trials in 2025: the Phase 1/2 VBP301 trial of VCAR33ALLO in H1 and the Phase 1/2a VBP101 trial of trem-cel with Mylotarg in H2. Both Hoffman and RA Capital Management will receive one board seat and one board observer seat. The funding extends Vor Bio's cash runway through the release of these trial updates.
Vor Bio has released updated clinical data from its Phase 1/2 VBP101 study of trem-cel followed by Mylotarg in relapsed/refractory AML patients. The study showed promising results with 25 patients treated with trem-cel, of which 15 received Mylotarg. Key findings include improved relapse-free survival, successful blood system shielding, and reliable engraftment with 100% of patients achieving primary neutrophil engraftment (median 9.5 days).
The company received supportive feedback from the FDA regarding their registrational trial design, with agreement on study population, control arm, primary endpoint, stratification factors, and statistical design. The FDA acknowledged trem-cel's neutrophil and platelet engraftment capabilities and its safety profile comparable to unedited CD34+ grafts.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in the Stifel 2024 Healthcare Conference. The company will engage in a fireside chat scheduled for Monday, November 18, 2024, at 2:25 pm ET in New York, NY. Additionally, Vor Bio will host one-on-one investor meetings during the conference. Interested parties can access both live webcast and archived replay of the fireside chat through the investors section of the company's website at www.vorbio.com.
Vor Bio reported Q3 2024 financial results and corporate updates. The company's net loss decreased to $27.6M from $33.2M year-over-year. Cash position stands at $62.8M, projected to fund operations into H2 2025. R&D expenses decreased to $21.8M from $27.6M, while G&A expenses reduced to $6.7M from $7.7M. Clinical progress includes 25 patients dosed with trem-cel and 6 patients receiving Mylotarg at 2 mg/m2. The company appointed Han Choi as CFO and plans to present updated clinical data at the upcoming ASH annual meeting.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has appointed Han Choi, M.D., LL.M., as its new Chief Financial Officer. Dr. Choi brings over 25 years of experience in investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. He will report directly to the company's President and CEO, Dr. Robert Ang.
Dr. Choi's expertise includes structuring corporate partnerships, managing complex transactions, and capital markets strategy. Prior to joining Vor Bio, he was a Principal at Oracle Investment Management, Inc., a healthcare-focused hedge fund. He has also held positions at Pharmacia and Bristol-Myers Squibb Company. Dr. Choi received his M.D. from Mount Sinai School of Medicine and law degrees from Oxford University and Harvard Law School.
PureTech Health's Founded Entity, Vor Bio (Nasdaq: VOR), announced new clinical data from its ongoing Phase 1/2 VBP101 study of trem-cel followed by Mylotarg in relapsed/refractory AML patients. The data showed:
- Reliable engraftment with 100% primary neutrophil engraftment
- High CD33 editing efficiency (median 89%)
- Shielding of the blood system across multiple Mylotarg doses
- Broadened therapeutic index for Mylotarg
- Early evidence of patient benefit in relapse-free survival
Vor Bio plans to discuss a pivotal trial design with the FDA by year-end. The company also reported progress with VCAR33ALLO and introduced a new preclinical asset, VADC45, targeting CD45 for various blood disorders.
Vor Bio (Nasdaq: VOR) has announced promising clinical data from its Phase 1/2 VBP101 study of trem-cel followed by Mylotarg in relapsed/refractory AML patients. The data showed reliable engraftment, shielding from Mylotarg toxicity, and early evidence of patient benefit. Key findings include:
- 100% primary neutrophil engraftment (median 9 days)
- High CD33 editing efficiency (median 89%)
- Maintained blood cell counts across multiple Mylotarg doses
- Broadened therapeutic index for Mylotarg
Vor Bio plans to discuss a pivotal trial design with the FDA by year-end. The company also reported progress with VCAR33ALLO and introduced a new preclinical asset, VADC45, targeting CD45 for various applications in oncology, gene therapy, and autoimmune disorders.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in three upcoming investor conferences in New York, NY. The events include:
1. Morgan Stanley 22nd Annual Global Healthcare Conference - 1x1 Investor Meetings on Friday, September 6, 2024
2. Baird 2024 Global Healthcare Conference - Fireside Chat on Wednesday, September 11, 2024, at 7:55am ET
3. Chardan's 8th Annual Genetic Medicines Conference - Fireside Chat on Monday, September 30, 2024, at 4:30pm ET
These conferences provide Vor Bio with opportunities to engage with investors and showcase their latest developments in cell and genome engineering.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
What is Vor Biopharma Inc. known for?
What are the main products of Vor Biopharma Inc.?
Where is Vor Biopharma Inc. located?
What recent achievements has Vor Biopharma Inc. made?
What clinical trials are currently being conducted by Vor Biopharma Inc.?
What is the potential impact of Vor Biopharma Inc.'s platform?
How can I stay updated on Vor Biopharma Inc.'s progress?
What financial updates were provided by Vor Biopharma Inc. recently?
What upcoming milestones is Vor Biopharma Inc. expecting?
What collaborations has Vor Biopharma Inc. entered into?
